INSMED Inc (INSM) stock
Close on Nov 13, 2026Market cap $26.58BP/E –Yield –
INSMED Inc grew revenue 240.0% to $1.52B over the twelve months to Sep 30, 2026. Free cash flow was -$627.58M. At the latest close the market valued the company at $26.58B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $26.58B
- P/E ratio
- –
- Price to sales
- 17.49
- Price to book
- 36.60
- Dividend yield
- –
- Free cash flow yield
- -2.36%
Fundamentals
- Revenue
- $1.52B
- Net income
- -$605.61M
- EPS, diluted
- -$2.82
- Free cash flow
- -$627.58M
- Book value per share
- $3.32
- Diluted shares
- 219M
Trading
- Next earnings
- Feb 18, 2027 (estimated, before the open)
- Previous close
- $118.07
- Open
- $118.18
- Day's range
- $116.97 – $121.54
- Volume
- 1,543,624
- Average volume (20 days)
- 3,772,429
- Index membership
- Russell 1000 (since Jun 2025), Russell 3000
- Beta (5 years)
- 0.75
- 52-week range
- $90.39 – $212.75
- RSI (14 days)
- 65.0
- Volatility (1 year)
- 63.0%
- Relative volume
- 0.54×
- WACC
- 8.9%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | INSM | S&P 500 | Difference | INSM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +25.2% | -3.0% | +28.2 pts | ||
| 3 months | -4.1% | -2.8% | −1.3 pts | ||
| Year to date | -30.4% | +11.5% | −41.9 pts | ||
| 1 year | -36.6% | +13.5% | −50.0 pts | ||
| 3 years | +406.9% | +77.7% | +329.2 pts | +71.8% | +21.1% |
| 5 years | +280.3% | +72.6% | +207.7 pts | +30.6% | +11.5% |
| 10 years | +738.5% | +308.2% | +430.3 pts | +23.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Insmed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Insmed
Pharmaceutical Preparations
This biopharmaceutical company focuses on discovering, developing, and commercializing novel therapies for serious respiratory, immunological, inflammatory, and rare diseases. Its commercial portfolio features two approved products: ARIKAYCE, an inhaled liposomal antibacterial treatment for refractory Mycobacterium avium complex lung infections, and BRINSUPRI, an oral daily tablet indicated for non-cystic fibrosis bronchiectasis. The company also advances a clinical pipeline that includes TPIP, an inhaled dry-powder prodrug formulation targeting pulmonary arterial hypertension and related interstitial lung disorders, alongside gene therapy candidates for rare conditions such as Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its primary end customers are adult and adolescent patients experiencing severe, chronic, and debilitating diseases with limited existing treatment alternatives.
Company profile, executives and historyInsmed stock: common questions
What is Insmed's stock price?
INSM closed at $121.16 on Nov 13, 2026, up 2.62% on the day. Over the past 52 weeks it traded between $90.39 and $212.75.
What is Insmed's market cap?
Insmed was worth $26.58B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is INSM's P/E ratio?
Insmed lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.82), so it has no meaningful P/E ratio.
How much revenue does Insmed make?
Insmed reported revenue of $1.52B for the twelve months to Sep 30, 2026, up 240.0% from a year earlier.
Does Insmed pay a dividend?
No. Insmed has not paid a cash dividend over the last twelve months.
When does Insmed report earnings next?
Insmed is expected to report Q4 FY2026 results on Feb 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has INSM stock performed over the past year?
Including dividends, INSM returned -36.6% over the past year, against +13.5% for the S&P 500.
How many INSM shares are sold short?
14M shares were sold short at the latest FINRA report, 6.48% of the float, or 3.6 days of average trading volume.
Who are Insmed's competitors?
Companies most similar to Insmed by business, industry and size include PTCT, IONS, BBIO, KNSA, SRPT.
See a number that looks wrong?